How Brain Trauma Triggers Lung Damage and a Promising Path to Prevention
Summary
- Up to 30% of TBI patients develop acute lung injury or its more severe form, acute respiratory distress syndrome.
- Researcher Dr. Nadine Kerr has identified a brain-lung inflammasome axis, where brain-derived extracellular vesicles act as inflammatory messengers that damage lung tissue.
- Dr. Kerr’s findings are impacting clinical approaches, including that of Dr. Kristine O’Phelan, who is using enoxaparin in traumatic brain injury patients to prevent thromboembolic events.
Traumatic brain injury (TBI) is a leading cause of death and disability worldwide. While its neurological consequences are well known, a growing body of research reveals that TBI can also elicit damage far beyond the brain, particularly in the lungs. Up to 30% of TBI patients develop acute lung injury or its more severe form, acute respiratory distress syndrome. Both significantly increase mortality.
But how does a brain injury lead to lung failure?
Recent studies from researchers led by Nadine Kerr, Ph.D., research assistant professor of neurological surgery at the University of Miami Miller School of Medicine, have identified a biological signaling cascade known as the neural-respiratory inflammasome axis. This axis links brain trauma to systemic inflammation and lung damage via tiny molecular messengers called extracellular vesicles (EVs), which Dr. Kerr discovered while earning her Ph.D. in neuroscience at the Miller School under the mentorship of Robert Keane, Ph.D., professor of physiology and biophysics at the Miller School, and W. Dalton Dietrich, Ph.D., professor of neurological surgery at the Miller School and scientific director of The Miami Project to Cure Paralysis.
The Science Behind the Signal
When the brain is injured, it releases EVs—microscopic, lipid-bound particles that carry proteins, RNA and other cellular cargo. These vesicles cross the blood-brain barrier and enter the bloodstream, where they can interact with cells in distant organs. In TBI patients, EVs are enriched with inflammasome proteins, a key component of the acute inflammatory response after injury.
In one study, Dr. Kerr and colleagues analyzed EVs from the blood of 21 TBI patients. They found that patients with lung injury had significantly higher levels of inflammasome proteins in both serum and EVs compared to those without lung complications. When these EVs were introduced to human lung endothelial cells in vitro, they triggered inflammasome activation. That led to pyroptosis, a form of programmed cell death associated with inflammasome signaling.
This discovery supports the existence of a brain-lung inflammasome axis, where brain-derived EVs act as inflammatory messengers that damage lung tissue. The implications suggest that lung injury after TBI is not merely a side effect of mechanical ventilation or systemic stress but a direct consequence of molecular signaling from the brain.
Blocking the Cascade with Enoxaparin
Building on this insight, a second study explored whether enoxaparin, an FDA-approved low molecular weight heparin commonly used to prevent blood clots, could interrupt this inflammatory cascade. In a mouse model of severe TBI, researchers administered enoxaparin 30 minutes after injury and examined its effects on lung and brain tissue 24 hours later.
Enoxaparin significantly reduced levels of inflammasome proteins caspase-1 and IL-1β in both the brain and lungs. It also preserved lung structure, lowered acute lung injury scores and decreased infiltration of inflammatory cells like neutrophils and macrophages.
These findings suggest that enoxaparin not only prevents clotting but also blocks EV uptake, thereby reducing inflammasome activation and lung damage.
A New Lens on TBI Management
Together, these studies demonstrate how TBI-induced EVs can trigger lung injury and how enoxaparin may offer a way to attenuate it. The research also highlights the potential of inflammasome proteins as biomarkers for predicting lung complications in TBI patients.
Kristine O’Phelan, M.D., professor of neurology and chief of the Neurocritical Care Division at the Miller School, was a member of Dr. Kerr’s Ph.D. thesis committee and has taken a keen interest in these findings from a clinical perspective.
Dr. O’Phelan is using enoxaparin in acutely injured TBI patients to prevent thromboembolic events such as deep vein thrombosis and pulmonary embolism. The research suggests that enoxaparin may also reduce lung complications by blocking EV-mediated inflammasome activation. This dual benefit—anticoagulant and anti-inflammatory—could reshape how clinicians manage TBI patients at risk for respiratory failure.
“It is exciting to consider that using enoxaparin for routine prophylaxis of thromboembolic complications may also help our patients by preventing pulmonary complications as well,” said Dr. O’Phelan.
This research suggests that enoxaparin may also reduce lung complications by blocking EV-mediated inflammasome activation. This dual benefit—anticoagulant and anti-inflammatory—could reshape how clinicians manage TBI patients at risk for respiratory failure.
Tags: Acute Respiratory Distress Syndrome, clinical trials, Department of Neurological Surgery, Department of Neurology, Dr. Kristine O'Phelan, Dr. Nadine Kerr, neurological surgery, neurology, The Miami Project to Cure Paralysis, traumatic brain injury